Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Rocket Pharmaceuticals (RCKT) Amortization - Intangibles (2018 - 2025)

Rocket Pharmaceuticals (RCKT) has disclosed Amortization - Intangibles for 8 consecutive years, with $1.2 million as the latest value for Q4 2025.

  • Quarterly Amortization - Intangibles fell 1.23% to $1.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $7.3 million through Dec 2025, down 9.67% year-over-year, with the annual reading at $7.3 million for FY2025, 9.67% down from the prior year.
  • Amortization - Intangibles hit $1.2 million in Q4 2025 for Rocket Pharmaceuticals, down from $1.7 million in the prior quarter.
  • In the past five years, Amortization - Intangibles ranged from a high of $3.3 million in Q4 2023 to a low of -$801000.0 in Q4 2021.
  • Historically, Amortization - Intangibles has averaged $1.2 million across 5 years, with a median of $1.5 million in 2024.
  • Biggest five-year swings in Amortization - Intangibles: tumbled 1130.65% in 2021 and later skyrocketed 1560.9% in 2023.
  • Year by year, Amortization - Intangibles stood at -$801000.0 in 2021, then surged by 234.96% to $1.1 million in 2022, then skyrocketed by 202.96% to $3.3 million in 2023, then crashed by 62.66% to $1.2 million in 2024, then decreased by 1.23% to $1.2 million in 2025.
  • Business Quant data shows Amortization - Intangibles for RCKT at $1.2 million in Q4 2025, $1.7 million in Q3 2025, and $2.2 million in Q2 2025.